Now I have a thorough understanding of the paper. Let me produce the consolidated review.

## Summary

This paper introduces ProteinVista, a 3D CNN that processes full-atom protein structures by voxelizing heavy atoms into a 3D grid, pre-trained on ~500K AlphaFold2 structures using a contrastive objective aligned with ESM-2 embeddings. The model (123M parameters) matches or outperforms ESM-2 on enzyme-substrate classification and transporter-substrate classification, and substantially outperforms ESM-2 on drug-target IC₅₀ regression (R² 0.69 vs 0.61). An ensemble with ESM-2 further improves classification performance, and a compute analysis shows ProteinVista is 20–40× faster to train than ESM-2 despite comparable FLOPs, challenging the assumption that full-atom 3D CNNs are computationally impractical.

## Strengths

1. **Compute and data efficiency demonstrated convincingly.** Section 4.3 (Fig. 3) shows ProteinVista processes 1,000 proteins on an A100 in 20s vs. 426s for ESM-2₆₅₀M, and pre-training used ~1% of the GPU-hours. This directly supports the claim that full-atom 3D CNNs are tractable at scale — a nontrivial and practically valuable finding.

2. **Clear improvement over sequence-only models on affinity prediction.** On the BindingDB IC₅₀ task (Table 2), ProteinVista achieves R² = 0.69 vs. ESM-2₆₅₀M's 0.61 (a ~13% relative gain) with Wilcoxon p < 10⁻³⁰⁴. This gap is large enough to be practically meaningful for drug-target interaction screening.

3. **Well-demonstrated complementarity between structure and sequence signals.** The ESM-ProteinVista ensemble consistently outperforms both individual models across all metrics in Table 1. The stratified analysis by sequence identity and TM-score (Fig. 2a–b) further confirms that structure and sequence capture partially orthogonal information — a genuinely insightful finding.

4. **Ablation studies quantitatively justify key design choices.** The ablation in Section 4.2 (Fig. 2e) measures the contribution of multi-view inference (-6.4% R² with 1 vs. 5 views), voxel resolution (-1.1% at 1.5Å), and pretraining objective (-1.0% for Rosetta vs. contrastive). These numbers ground the architectural decisions in evidence rather than intuition.

5. **Honest evaluation of failure modes.** Section 3.4's GO annotation experiment — where ProteinVista underperforms ESM-2 (Fmax 0.57 vs. 0.62) — is a scientifically credible addition that delineates the model's scope rather than hiding limitations.

## Weaknesses

### Fatal
None.

### Major

1. **Missing structural baselines on the IC₅₀ regression task.** The paper claims to advance "drug-target interaction prediction" but the IC₅₀ experiment (Table 2) compares only against sequence-based ESM-2. Without comparison to any structure-aware method (e.g., 3D GNNs such as SchNet/EGNN/TorchMD-Net, physics-based docking scores, or existing structure-dependent DTI predictors), it is impossible to assess whether the improvement is due to the 3D architecture specifically or simply to having more parameters / a better training pipeline than ESM-2. The Rosetta-pretrained ablation (R² 0.68) partially addresses this by removing the ESM-2 distillation channel, but a direct structural baseline is needed. This gap weakens the broader claim that the method "surpasses current best methods for tasks that depend on fine structural details."

2. **The state-of-the-art comparison on classification benchmarks uses an asymmetric ensemble.** The ESM-ProteinVista<sub>OP</sub> results that surpass SPOT and ProSmith-ESP (Table 1) are obtained by combining ProteinVista *and* ESM-2₆₅₀M embeddings through a contrastive classifier and averaging — an ensemble not afforded to the competing methods. While the paper is transparent about the OP pipeline, the comparison is not controlled: it conflates the contribution of the proposed architecture with the contribution of multi-model ensembling and additional ESM-2 signal. The standalone ProteinVista (without ESM-2) underperforms SPOT on TSP (90.8% vs. 92.4%) and ProSmith-ESP on ESP (91.8% vs. 94.2%). The paper should either (a) benchmark the competing methods with a corresponding ESM-2 ensemble, or (b) clearly separate the architecture claim from the ensemble claim.

### Minor

1. **No variance estimates on primary metrics.** Tables 1 and 2 report single values for all metrics with no standard deviations, confidence intervals, or run counts. The margins most critical to the paper's claims are small enough to be vulnerable to run-to-run noise (e.g., TSP: ProteinVista 90.8% vs. ESM-2₆₅₀M 89.3% — a 1.5% gap; ESP: 91.8% vs. 91.9% — essentially tied). The McNemar and Wilcoxon tests demonstrate that predictions are statistically different, but they do not quantify variance in model training. Multiple seeded runs with reported variance would substantially strengthen the evidence.

2. **The claim "outperforms sequence transformers on three benchmarks" is slightly overstated for the enzyme-substrate task.** On ESP, ProteinVista alone achieves 91.8% accuracy vs. ESM-2₆₅₀M's 91.9% (Table 1) — essentially tied. The paper accurately uses "surpasses or equals" in the body text, but the abstract's "outperforms... on three benchmarks" is imprecise for this task.

3. **Contrastive pretraining partially distills sequence-model knowledge into the structure encoder.** Because the default ProteinVista is pretrained to align its embeddings with ESM-2, the downstream performance of this variant partially reflects signal inherited from ESM-2. The Rosetta-pretrained variant (R² 0.68) provides a cleaner test of pure structure encoding and is only 1% behind the contrastive variant (R² 0.69), which is an important point that somewhat undercuts the "architecture alone" framing. The paper could better emphasize this distinction.

4. **No GNN baseline despite criticizing GNNs in the introduction.** The introduction argues that GNN-based protein encoders lose atom-level detail, but no standard geometric/equivariant GNN (SchNet, EGNN, TorchMD-Net) is benchmarked in a controlled setting. Including such a baseline would directly test the paper's stated motivation.

### Trivial
None.

## Nice-to-Haves

- **Linear probing evaluation**: A frozen-encoder experiment with a trained linear head would isolate the quality of the pretrained representation from the fine-tuning procedure. This is not a requirement but would strengthen the case that the 3D CNN autonomously extracts useful geometry.
- **GNN baseline on IC₅₀**: As noted above, this would directly test the paper's motivation.
- **Discussion of rotation augmentation scope**: The paper could briefly note that the 90° / mirror scheme covers the cubic dihedral group (48 orientations) rather than full SO(3), and discuss whether this is sufficient for the protein domains tested.

## Removed Points

These points are flagged to be removed; treat them with caution.

1. **"Rotation augmentation misrepresented as general invariance"** (from Harsh Critic Point 3): The critic argues that the 90° / mirror augmentation scheme is "misrepresented" as general rotation invariance. However, the paper's language is cautiously aspirational: the abstract says "rotation-robust" (not "fully invariant"), the introduction says "aimed to achieve rotation-invariant predictions" (describing a goal), and Section 2.4 clearly describes the specific scheme. The ablation confirms multi-view averaging is essential. The discrepancy between claim and implementation is modest and not deceptive. **Removed** because the criticism overstates the gap between the paper's language and its implementation.

2. **"The paper's claims are structurally flawed / systematic overclaiming that invalidates the paper"** (from Harsh Critic Point 1's framing): The critic argues the experimental design is "structurally flawed" and the paper "should not be accepted in its current form." However, the core claims (outperforming sequence transformers, compute efficiency, complementarity) are well-supported. The overclaiming is limited to the introduction's "current best methods" phrasing and the OP ensemble comparison. These are real weaknesses (addressed in the Major/Minor sections above) but they do not invalidate the paper's contribution; they are presentation gaps, not experimental fraud. **Removed** the fatal framing, preserved the substantive concerns as Major and Minor weaknesses above.

## Novel Insights

None beyond the paper's own contributions. The reviews surface the expected tension between the paper's ambitious framing and the actual experimental controls, but do not add a genuinely new perspective that the paper itself does not articulate.

## Suggestions

1. **Add structural baselines on IC₅₀.** Even a single equivariant GNN (e.g., TorchMD-Net) under the same training setup would contextualize the improvement over ESM-2 and directly test the paper's architectural motivation.
2. **Run the SOTA comparison with controlled baselines.** If the OP pipeline includes ESM-2, check whether SPOT/ProSmith-ESP also improve when augmented with ESM-2 embeddings. Report standalone ProteinVista vs. SOTA clearly in the main table.
3. **Report variance.** Run 3–5 fine-tuning seeds with different random initializations and report mean ± std for the main metrics.
4. **Tone down the introduction's "current best methods" claim** to match the evidence, or add the missing baselines needed to support it.
5. **Explicitly note the rotation augmentation limitation** (48 discrete orientations, not full SO(3)) in Section 2.4 and discuss any potential residual orientation bias.

## Score and Decision

The paper presents a genuinely valuable contribution: it demonstrates that a well-engineered full-atom 3D CNN can be both compute-efficient and competitive with (and on some tasks clearly superior to) much larger sequence transformers, and it provides actionable ablation evidence for why. The weaknesses are real but addressable — missing baselines, lack of variance reporting, and overclaiming in specific phrasings — and do not undermine the core finding that 3D CNNs are independently viable and complementary to sequence models. The compute efficiency result alone is a practically important counterpoint to prevailing wisdom.

MY FINAL SCORE: <score>6.5</score>
MY FINAL DECISION: <decision>Accept</decision>